ReviewCancers2020
Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Head-to-head comparison of the diagnostic performance betweenAbdominal radiology (New York) · 2024Pooled it
- Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?Contrast media & molecular imaging · 2022Pooled it
- Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus [International journal of molecular sciences · 2021Pooled it
- Increased uptake ofEuropean journal of nuclear medicine and molecular imaging · 2022Trial
- Automated and manual synthesis of [EJNMMI radiopharmacy and chemistry · 2026Article
- "FAPI-PET: a new chapter in oncologic molecular imaging".Annals of medicine and surgery (2012) · 2026Article
- Theranostics 2.0: Target-driven, artificial intelligence-enabled cancer therapy across tumor types.Diagnostic and interventional imaging · 2025Review
- Production and Quality Control of [Pharmaceuticals (Basel, Switzerland) · 2025Article
- Protein-based Radiopharmaceuticals that target fibroblast activation protein alpha: a review of current progress.EJNMMI radiopharmacy and chemistry · 2025Review
- Cryo-electron microscopy reveals a single domain antibody with a unique binding epitope on fibroblast activation protein alpha.bioRxiv : the preprint server for biology · 2024Article
- Automated Radiosynthesis of [Pharmaceuticals (Basel, Switzerland) · 2024Article
- Dual-tracer PET/CT protocol with [Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024Article
- The comparative utility of FAPI-based PET radiotracers over [American journal of nuclear medicine and molecular imaging · 2024Review
- Efforts toward PET-Activatable Red-Shifted Silicon Rhodamines and Silicon Pyronine Dyes.Pharmaceuticals (Basel, Switzerland) · 2023Article
- PET Imaging of Fibroblast Activation Protein in Various Types of Cancer UsingJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- PET tracers in glioblastoma: Toward neurotheranostics as an individualized medicine approach.Frontiers in nuclear medicine · 2023Review
- Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy.European journal of nuclear medicine and molecular imaging · 2022Article
- Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy.European journal of nuclear medicine and molecular imaging · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small molecules targeting fibroblast activation protein (FAP) have emerged as a new group of tracers for positron emission tomography (PET) in 2018. The purpose of this systematic review is therefore to summarize the evidence that has been gathered to date in patients and to discuss its possible implications for radiotherapy planning. The MEDLINE database was searched for the use of FAP-specific PET in cancer patients and the records were screened according to PRISMA guidelines. Nineteen studies were included. While dedicated analyses of FAP-specific PET for radiotherapy planning were available for glioblastoma, head and neck cancers, lung cancer, and tumors of the lower gastrointestinal tract, there is still very limited data for several epidemiologically significant cancers. In conclusion, FAP-specific PET represents a promising imaging modality for radiotherapy planning that warrants further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.